drugset
drugset / Trial / NCT01487135

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

NCT01487135 ↗

Phase 1 Completed 60 enrolled FORUM Pharmaceuticals Inc Quintiles, Inc. · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of EVP-6124 at therapeutic and supratherapeutic concentrations on cardiac repolarization in healthy subjects.

Timeline

Start
2011-12
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator ENCENICLINE Small molecule 8 mg Oral
Comparator ENCENICLINE Small molecule 80 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.